Molecular Cytogenetics Market Competitive Landscape Analysis with Forecast by 2023

Global molecular cytogenetics market is forecasted to attain revenue of $3.3 billion by 2023. The market is mainly driven by growing implementation of pharmacogenomics in personalized disease management and drug development, rising cancer cases, advancements in cytogenetic techniques, and rise in genetic-based prediction of chromosomal abnormalities.

Download free report sample at: https://www.psmarketresearch.com/market-analysis/molecular-cytogenetics-market/report-sample

Based on offering, the molecular cytogenetics market has been categorized into consumables, software and services and instruments. Globally, the market for software and services is expected to register fastest growth, with CAGR of 10.5% during the forecast period. This can be attributed to rapid adoption of automation in laboratory process and rising preference for outsourcing of expensive services.

Based on technology, the molecular cytogenetics market has been categorized into comparative genomic hybridization (CGH), fluorescence in-situ hybridization (FISH), immunohistochemistry, karyotyping and others. The karyotyping technology market for molecular cytogenetics is further categorized into spectral and virtual. In 2017, spectral karyotyping held larger share, of 66.0%, in molecular cytogenetics market, owing to the usage of these technique for the detection of complex chromosomal aberration as well as for identification of new leukaemia subgroups.

Browse report at: https://www.psmarketresearch.com/market-analysis/molecular-cytogenetics-market

Globally, key players in the molecular cytogenetics industry are developing new instruments and tests for the molecular diagnosing, genetic screening and other tests. For instance, in July 2017, Quest Diagnostics announced the launch of a genetic screening service, QHerit. The service is for the detection of genetic risk associated to offspring through passing of heritable disorders. The QHerit Pan-Ethnic Expanded Carrier Screen is a panel of tests for the 22 heritable diseases cited under new screening guidelines issued in March 2017 by the American College of Gynecology (ACOG).

Some of the other key players operating in the molecular cytogenetics industry include Abbott Laboratories, Danaher Corporation, Bio-Rad Laboratories Inc., F. Hoffmann La-Roche AG, PerkinElmer Inc., Illumina Inc, Agilent Technologies Inc and NeoGenomics Inc.

Source: P&S Intelligence

Topical Drug Delivery Market to Witness the Highest Growth Globally in Upcoming Years

Drugs that are applied to a local area on the body are known as topical drugs. Many creams and balms that are used for skin treatment are frequently called topical drug. Topical drug delivery market offers an alternative drug delivery system to treat many diseases and related conditions such as psoriasis, ringworm, rashes & blisters and others. The topical drug delivery has turned out to be progressively essential in the pharmaceutical industry. Eye drops for ophthalmic use and various drugs utilized for inward breath in respiratory conditions such as asthma are also frequently known as topical medications. Topical medications have a local effect that means the effect of the drug will be only in the area where the drug has been applied; however, some topical medications can also have a systemic effect.

Browse report sample at: https://www.psmarketresearch.com/market-analysis/topical-drug-delivery-market/report-sample

The global topical drug delivery market is segmented on the basis of the product type, route of administration, indication for which the drug is used and its end users. Based on product type the market is segmented into formulations and devices, formulations are further sub-segmented into solid, liquid and semi-solid formulations, and devices. Semi-solid formulations include ointment, cream, gel lotion and paste and had a major contribution in the global topical drug delivery market in 2016, as compared to other sub-segments. The major factors driving the growth of semi-solid formulations include increasing rate of blood donations and rise in the number of surgical procedures such as organ transplantation where these formulations are widely used.

There are various factors that drive the growth of the topical drug delivery market including the increasing prevalence of dermal diseases, development of high technology in topical drug delivery systems, high number of cases of burn injuries, and increasing prevalence of diabetes, globally. According to the World Health Organization (WHO), the prevalence of diabetes among adults over 18 years of age has risen from 4.7% in 1980 to 8.5% in 2014, globally. Also, the WHO estimates that, diabetes would be the seventh leading cause of death, by 2030.

Browse report at: https://www.psmarketresearch.com/market-analysis/topical-drug-delivery-market

The high emergence and prevalence of novel diseases has led to the development of new medicines, and different companies are collaborating to strengthen their position in the market.

In January 2017, the United States Food and Drug Administration approved Rhofade (oxymetazoline hydrochloride) manufactured by Allergan plc for the topical treatment of persistent facial erythema associated with rosacea in adults. Rhofade is cream based formulation intended for topical administration.

Some of the other key players operating in the global topical drug delivery market include Crescita Therapeutics Inc., SOLVAY S.A., Bayer AG, Cipla Limited, Galderma S.A, GlaxoSmithKline PLC, Janssen Global Services, LLC. (Johnson and Johnson), Novartis International AG, Sienna Biopharmaceuticals, Inc., Allergan PLC.

Source: P&S Intelligence

At-Home DOA Testing Market - New Business Opportunities & Investment Research Report 2023

Global at-home DOA testing market is projected to attain a size of $831.9 million by 2023. The market is mainly driven by the increased production and trade of illicit drugs worldwide, growing use of illicit drugs amongst teenagers, and initiatives by government organizations to reduce the level of drug abuse.

Download free report sample at@  https://www.psmarketresearch.com/market-analysis/at-home-doa-testing-market/report-sample

On the basis of various types of products, the at-home DOA testing market has been categorized into rapid DOA test kits and breath analyzers. The market for rapid DOA test kits is expected to witness faster growth during the forecast period, attributed to the increasing adoption of various types of rapid DOA test kits, including test cups and dip cards. Also, these test kits are much cheaper as compared to breath analyzers.

Further, the rapid DOA test kits are bifurcated into test cups, test strips, test dip cards, and other types of kits. Amongst all these, the DOA test cups dominated the global rapid DOA test kits market in 2017. Extensive use of test cups for at-home urine drug testing is a key factor driving the market for this product category.

Browse full report at@  https://www.psmarketresearch.com/market-analysis/at-home-doa-testing-market ​​​​​​​

The companies operating in the at-home DOA testing industry are acquiring other firms and establishing their presence in different economies to increase their market share. Abbott Laboratories (Abbott) being a major player in the production of at-home DOA testing products acquired Alere Inc. in 2017, to increase its share in the point-of-care testing diagnostics market. The addition of this business aligns with Abbott's strategy for the growth of company and complements the leadership positions across its other businesses, which include medical devices, nutritional supplements, and pharmaceuticals.

Some of the other key players in the at-home DOA testing industry are UCP Biosciences Inc., Orient New Life Medical Co. Ltd., Express Diagnostics Int’l Inc., Assure Tech (Hangzhou) Co. Ltd., Psychemedics Corporation, Confirm BioSciences, Phamatech Inc., Home Health (U.K.) Ltd., and Quest Products Inc.

Source: P&S Intelligence

Surgical Site Infection Market to Grow at a Brisk rate in the Foreseeable Future

Global surgical site infection market is forecasted to reach $5.9 billion by 2023. The market growth can be attributed to the development of technologically advanced products and growing geriatric population. Furthermore, increasing number of surgical procedures and rising incidence of SSIs are boosting the market growth.

Request for report sample at: https://www.psmarketresearch.com/market-analysis/surgical-site-infection-market/report-sample

Antibiotic prophylaxis products generated the largest revenue in the surgical site infection market in 2017. In most cases, patients’ sensitivity to certain drugs creates the need for specific antibiotics, which, in turn, adds to the treatment cost. Owing to this factor, antibiotic prophylaxis products continue to be in high demand in the market. However, the fastest growth in the market during the forecast period is expected from the antiseptic and disinfectant product category, with a CAGR of 7.4%.

Among all phases, the demand for products for the intraoperative phase is expected to exhibit the fastest growth in the surgical site infection market, at a CAGR of 6.6%, during the forecast period. This can be attributed to the wide usage of SSI preventive products during the intraoperative phase, as the chances of contamination to open wounds are the highest during this phase. Also, due to this reason, healthcare facilities are increasingly complying with the World Health Organization (WHO) guidelines that suggest measures to prevent infections.

Hospitals have been contributing the largest revenue to the surgical site infection market, owing to increase in the number of surgeries and a significant increase in the number of hospitals on a global level, which is further leading to the increased use of products that help prevent surgical site infections.

Some of the other key players operating in the surgical site infection market are 3M Company, STERIS plc, Stryker Corporation, Medtronic plc, Prescient Surgical Inc., Covalon Technologies Ltd., Surgical Site Infection Prevention LLC, HARTMANN GROUP, B. Braun Melsungen AG, and Becton, Dickinson and Company.

Source: P&S Intelligence

ADME-Toxicology Testing Market Analysis, Share and Future Scope

ADME stands for absorption, distribution, metabolism and elimination of the drug and chemicals define their nature in a human body. These four methods define the impact of a specific drug or chemical to the human tissues. Toxicology testing is an important phenomenon before introducing new medicine to the market. ADME toxicology facilitated pharmaceutical manufacturing company to minimize their drug discovery time, testing complications, and to reduce the cost of drug development.

Browse report sample at: http://bit.ly/2Nu7SYQ

ADME-toxicology testing has witnessed significant growth in the drug development in recent years. Most often the development of new drug is a very critical for the drug developers, attributed mainly to the high cost proposal for pharmaceutical and large attrition rate at various stages of drug development. The conventional drug development uses vivo model of toxicity testing.

Based on the different product type, global ADME-toxicology testing market can be bifurcated as instruments, software solutions, assays systems, reagents and others. Based on the technology used in the ADME-toxicology testing the market can be bifurcated as in-vivo (implemented inside a living organism), and in-vitro (test performed in a laboratory). Further In-vitro technology is bifurcated as biochemical testing and cell testing (including liver, intestinal, kidney). In-vitro technology is expected to witness the highest growth during the forecast period attributed mainly to the growing concern over animal rights for using animals for clinical trials. In-vivo is still the largest used toxicity testing technology owing to its cost and time benefits over other toxicity testing technique. With benefits such as increase throughput screening, the ADME toxicology prediction technology is expected to increase in coming years.

Browse report at: http://bit.ly/2H4CW0g

Asia Pacific is expected to be the fasted growing market of ADME-Toxicology Testing during the forecast period. The growth is mainly anticipated from the supporting government initiatives and increasing number of merger and accusation (M&A) in pharmaceutical companies and research laboratories.

Some of the major players operating in the Global ADME-Toxicology Testing Market include, Accelrys, Inc., Agilent Technologies, Inc., Caliper Life Sciences, Inc., Bio-Rad Laboratories, Inc., Beckman Coulter, Inc., Cellartis AB, Cyprotex PLC., Life Technologies Corporation, Optivia Biotechnology, Inc., Thermo Fisher Scientific, Inc., Molecular Discovery Ltd., Cyprotex PLC, MultiCASE, Inc., Promega Corporation, Xceleron, Inc., ACEA Biosciences, Inc., Albany Molecular Research, Inc., Beckman Coulter, Inc., CeeTox, Inc., Molecular Discovery Ltd.

Source: P&S Intelligence